Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

High-Priced Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs

But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.

Pharmacy Benefit Management Reimbursement

High-Priced New Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs

But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.

Pharmacy Benefit Management Reimbursement

How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

Pricing Debate Legislation

How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

Vaccines Pricing Debate

Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key

Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.

Reimbursement Cost Effectiveness

Novartis Payments For Kymriah Treatment Logistics Avoid Kickback Concerns

US HHS Office of Inspector General clears company program to provide travel expenses and lodging to needy patients located far from designated treatment centers.

Compliance Legal Issues
See All
UsernamePublicRestriction

Register